Implantica Secures FDA Approval for GERD Device RefluxStop, Entering US Market
Implantica AG has received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for its implant-based gastroesophageal reflux disease (GERD) treatment, RefluxStop®. This approval clears the way for commercial launch in the United States.
Implantica AG, a medical technology company, has obtained Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for its device, RefluxStop®. This implant-based treatment targets gastroesophageal reflux disease (GERD), a common digestive disorder.
The FDA approval marks a significant step for Implantica, as it permits the company to initiate commercial activities within the United States, which is considered the largest market for medical devices globally. The approval followed a comprehensive review of the RefluxStop® PMA application by the FDA.
RefluxStop® is designed to offer an alternative to existing GERD treatments. The device aims to provide a long-term solution for patients suffering from chronic acid reflux, addressing symptoms that often persist with conventional therapies like medication or lifestyle changes.
With this U.S. market entry secured, Implantica is expected to focus on establishing distribution channels and patient access programs. The company's strategic move into the American market could significantly impact its global presence and revenue streams in the coming years.